MBX Biosciences, Inc. Common Stock (MBX) Earnings History
Net Loss4 years of earnings data (2022–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
MBX Biosciences, Inc. Common Stock (MBX) Earnings Overview
As of June 28, 2026, MBX Biosciences, Inc. Common Stock (MBX) reported trailing twelve-month net income of -$87M, reflecting -28.6% year-over-year growth. The company earned $-1.86 per diluted share over the past four quarters.
Looking at the long-term picture, MBX's historical earnings data spans multiple years. The company achieved its highest annual net income of -$26M in fiscal 2022.
MBX Biosciences, Inc. Common Stock is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including CGEM (-$221M net income), KYMR (-$315M net income, -794.4% margin), PEPG (-$77M net income), MBX has comparable earnings metrics. Compare MBX vs CGEM →
MBX Earnings vs Peers
Earnings metrics vs comparable public companies
MBX Historical Earnings Data (2022–2025)
4 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$87M | -40.5% | -$98M | $-2.38 | - | - |
| 2024 | -$62M | -90.2% | -$68M | $-1.85 | - | - |
| 2023 | -$33M | -24.6% | -$35M | $-1.02 | - | - |
| 2022 | -$26M | - | -$25M | $-0.82 | - | - |
Download Data
Export MBX earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
4+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
MBX — Frequently Asked Questions
Quick answers to the most common questions about buying MBX stock.
What is MBX earnings per share (EPS)?
MBX trailing twelve-month (TTM) diluted EPS is $-1.86, reflecting -28.6% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2022 to 2025 is available in the table on this page.
What is MBX Biosciences, Inc. Common Stock's net income?
MBX Biosciences, Inc. Common Stock (MBX) trailing twelve-month net income is $-87M as of 2025. Earnings declined -28.6% year-over-year.
Is MBX profitable?
MBX is not currently profitable on a TTM basis, reporting a net loss of $-87M. Net margin is N/A. Investors should monitor for a return to profitability.
What is MBX's earnings growth rate?
MBX compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2022 to 2025.
What are MBX's profit margins?
MBX Biosciences, Inc. Common Stock net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -27.8%.
Is MBX growing earnings?
MBX earnings are declining — EPS fell -28.6% year-over-year. TTM net income dropped to $-87M. This contrasts with the 5-year CAGR of N/A.
What was MBX's best earnings year?
MBX Biosciences, Inc. Common Stock's highest annual net income on record is $-26M, achieved in fiscal year 2022. Earnings history on this page spans 2022 to 2025 and includes all annual and quarterly figures.
What were MBX's earnings last quarter?
MBX's most recent reported quarter was Q1 2026. Net income was $-24M with diluted EPS of $-0.50. For a full breakdown of all quarters, see the quarterly earnings table on this page.